Document Detail

Effects of lipoprotein(a) on thrombolysis.
MedLine Citation:
PMID:  8187238     Owner:  NLM     Status:  MEDLINE    
Lipoprotein(a) (Lp(a)) and plasminogen share a high degree of structural homology. Therefore it has been suggested that elevated levels of Lp(a) may inhibit the profibrinolytic activity at the cell surface and increase the risk of thrombosis by competitive inhibition of plasminogen. In the present study we evaluated whether high levels of Lp(a) affect thrombolytic therapy in patients with acute myocardial infarction. Forty-one patients with acute myocardial infarction were treated with a combination of recombinant tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Coronary patency was assessed angiographically 90 min after initiation of treatment. Thrombolysis was successful in 30 and unsuccessful in 11 patients. Patients with high Lp(a) levels (> 25 mg/dl) (n = 9) responded equally well to thrombolytic therapy (8 of 9, patency 89%) as did patients with normal or low levels of Lp(a) (22 of 32, patency 70%, difference P > 0.1). The results demonstrate that high levels of Lp(a) do not influence thrombolysis in patients with acute myocardial infarction when low-dose pharmacologic concentrations of recombinant tissue-type plasminogen activator and human single chain urokinase-type plasminogen activator are applied in combination.
E von Hodenberg; E Pestel; J Kreuzer; M Freitag; C Bode
Related Documents :
18020578 - Recombinant plasminogen activators: a comparative review of the clinical pharmacology a...
8427118 - Influence of thrombolytic therapy on the evolution of baroreflex sensitivity after myoc...
22703898 - Vagal nerve stimulation reduces anterior mitral valve leaflet stiffness in the beating ...
2526148 - Clinical management of acute myocardial infarction.
19344728 - Activation of the protective survivor activating factor enhancement (safe) pathway agai...
1401618 - Cardiac manifestations of cocaine abuse: a cross-sectional study of asymptomatic men wi...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Chemistry and physics of lipids     Volume:  67-68     ISSN:  0009-3084     ISO Abbreviation:  Chem. Phys. Lipids     Publication Date:  1994 Jan 
Date Detail:
Created Date:  1994-06-23     Completed Date:  1994-06-23     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0067206     Medline TA:  Chem Phys Lipids     Country:  IRELAND    
Other Details:
Languages:  eng     Pagination:  381-5     Citation Subset:  IM    
University of Heidelberg, Department of Cardiology, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Therapy, Combination
Fibrinogen / metabolism
Fibrinolysis / drug effects,  physiology*
Lipoprotein(a) / blood*
Myocardial Infarction / blood*,  drug therapy*
Plasminogen / metabolism
Recombinant Proteins / administration & dosage,  therapeutic use
Thrombolytic Therapy*
Tissue Plasminogen Activator / administration & dosage,  therapeutic use
Urokinase-Type Plasminogen Activator / administration & dosage,  therapeutic use
alpha-2-Antiplasmin / metabolism
Reg. No./Substance:
0/Lipoprotein(a); 0/Recombinant Proteins; 0/alpha-2-Antiplasmin; 9001-32-5/Fibrinogen; 9001-91-6/Plasminogen; EC Plasminogen Activator; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound...
Next Document:  Lipoprotein(a) and coronary heart disease.